Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE ...Middle East

SUZHOU, China, and ROCKVILLE, Md., June 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE)...

Hence then, the article about global registrational phase iii study of olverembatinib for the treatment of patients with sdh deficient gist approved by the china cde was published today ( Tuesday 11/06/2024 - 05:56 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE )

Also on site :

• The Retirement Habit Researchers Say Could Add Years to Your Life
• Dunkin’s Limited-Edition Tumbler Is Already in High Demand—How to Get Yours
• World Cup 2026: Day five